In the TME, pDCs are considered negative regulators of T cell responses, and their activation can induce the progression of anti-tumor immunity (32).Within the TME, CD8+ T cells are critical components of anti-tumor immunity, functioning as primary effector cells with indispensable therapeutic potential (33, 34). This evidence concerns the gene CD8A and neoplasm.